Silihan lan utang jangka dawa perusahaan Addex Therapeutics, Ltd. (ADXN)

This ADXN price chart illustrates the price action of an asset whose prospects depend on the development of allosteric modulators in partnership with major industry players, with the indicator standing at 0.00. The business model relies on outsourcing drug synthesis and testing to external contractors while maintaining its scientific headquarters in Switzerland. However, the lack of sales and the dependence on the success of the collaboration with Janssen create significant financial risks.

Long-term liabilities reflect the total volume of borrowed capital with a maturity exceeding twelve months. By analyzing the size of the company's long-term debt, an investor assesses the sustainability of financial leverage and liquidity risk. The current value of 0.00 captures the volume of credit resources directed toward scaling operations. This metric is critical for Addex Therapeutics (ADXN), which utilizes loans to fund the development of unique CNS molecules, thereby ensuring the growth of a closed scientific ecosystem for precision therapy.